CA-OMNI-CONVERSION
22.4.2021 06:10:08 CEST | Business Wire | Press release
Today, OMNI Conversion Technologies Inc. (OMNI CT) announced the first sale of its unprecedented waste to hydrogen product. The Larsen and Lam Climate Initiative, a foundation backed by philanthropists Chris Larsen and Lyna Lam, has committed $35 million to bring this ground-breaking technology to production in the fight against climate change. The first commercial plant in production from OMNI CT will use unsorted non-recyclable Municipal Solid Waste (MSW), which is currently disposed of in landfills, to produce negative carbon hydrogen in California.
New technologies are essential in the fight against climate change. While low-cost solar electricity was a dream only a decade ago, its impact today is far-reaching. The Larsen and Lam Climate Initiative investment will accelerate the global adoption of OMNI CT technology.
”Low or zero CO2 fuels are critical to achieving a decarbonized economy. OMNI CT has created a first-of-its-kind product that can have a global and immediate impact. This is why we are excited to work with their team to bring this technology to market in California as our first project from the Larsen and Lam Climate Initiative,” said Chris Larsen, Co-Founder of the Larsen and Lam Climate Initiative and Ripple.
“With surging global interest in hydrogen and biofuels and as the urgency grows around the climate change crisis, it’s an opportune time to be launching our product into the fight against climate change. We’ve spent 15 years and $400 million perfecting it. We’re thrilled to be working with the Larsen and Lam Climate Initiative who not only understand but share our vision for the future,” said Rod Bryden, CEO of OMNI CT.
Professor Daniel Kammen, Chair of the Energy and Resources Group at the University of California, Berkeley, commented that zero-carbon fuels are a critical part of the aggressive path to a clean economy. As California looks to build a vibrant zero-carbon economy, the Omni technology is an exciting addition that will solve multiple problems at once.
The Omni 200™ GPRS™ waste to hydrogen product can produce around 5000 tonnes of negative carbon hydrogen each year, from 200 tonnes a day of unsorted non-recyclable garbage. Hydrogen is produced in the city where it is needed and the garbage is diverted from landfill to OMNI CT and eliminated with no air emissions and nothing left for disposal. Energy in the garbage replaces electricity otherwise required to make green hydrogen. The circular hydrogen produced could operate some 550 city buses running on hydrogen at a cost less than the current cost of using gasoline or diesel.
The purchase was funded and signed on April 21, 2021 with the goal of being in production in California converting Municipal Solid Waste to hydrogen by the end of 2023.
About OMNI CT
OMNI CT is an Ottawa Canada-based company that has developed a proprietary technology by designing, building, testing, and operating a complete commercial demonstration plant from 2007-2014. The patented process converts any solid energetic material into OmniSyngas™ to produce clean green hydrogen, biofuels, synthetic natural gas, chemicals or electricity for the circular economy.
OMNI CT’s robust efficient OMNI200™ GPRS™ is providing a unique solution to achieving decarbonization targets.
The OMNI200™ Gasification & Plasma Refining System (GPRS™)
The OMNI200™ GPRS™ unit is proven at industrial scale. It is a complete integrated system, delivered to site in large modules, rather than stick-built. It receives and converts at a rate of 200 tonnes per day (67,000 tonnes per year) a wide variety and mix of energetic wastes into clean consistent syngas with a predictable heating value and composition. The H2/CO ratio can be tailored to the final application. Multiple units can be readily combined for larger plants.
OmniSyngas™
OmniSyngas™ is a precursor to the production of hydrogen and biofuels. Municipal solid waste has more than 50% biogenic content. This will produce green fuels and avoid methane from sending waste to landfills. Since methane has 25x the GHG effect of CO2, these fuels can be produced with a negative carbon footprint. Further reduction is possible by capturing and storing the CO2 in the syngas.
For additional details on Omni CT’s product: Download Product Description
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421006131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
